Does Semaglutide Burn Fat or Just Suppress Appetite? The Mechanism Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide does not directly burn fat through metabolic acceleration or thermogenesis
• It creates a sustained caloric deficit by suppressing appetite and slowing gastric emptying, which forces the body to metabolize stored adipose tissue
• DEXA scan studies show semaglutide patients lose 70-75% fat mass and 25-30% lean mass, compared to 50-50 splits in diet-only weight loss
• The medication preserves more muscle than traditional calorie restriction alone when combined with adequate protein intake and resistance training

Direct answer (40-60 words)

No, semaglutide does not burn fat directly. It works by activating GLP-1 receptors in the brain and gut, which suppresses appetite and slowers gastric emptying. This creates a caloric deficit that forces your body to metabolize stored fat for energy. The fat loss is real, but it's indirect, not pharmacological fat burning.

Table of contents

1. The mechanism: how semaglutide actually causes fat loss
2. What "fat burning" means (and what it doesn't)
3. The body composition data: what you actually lose
4. Why most articles conflate appetite suppression with fat burning
5. The metabolic rate question: does semaglutide speed up your metabolism?
6. Comparing semaglutide to actual fat burners (and why the distinction matters)
7. The muscle preservation advantage over diet alone
8. What happens to the fat: the lipolysis pathway explained
9. Clinical patterns: what FormBlends sees in real-world body composition tracking
10. The dose-response relationship for fat loss
11. When fat loss stalls and what it means
12. FAQ
13. Sources

The mechanism: how semaglutide actually causes fat loss

Semaglutide is a GLP-1 receptor agonist. It mimics the naturally occurring hormone glucagon-like peptide-1, which your intestines release after eating. When semaglutide binds to GLP-1 receptors in three key locations, it creates the conditions for fat loss:

1. Hypothalamic appetite centers. GLP-1 receptors in the arcuate nucleus and paraventricular nucleus of the hypothalamus regulate satiety. When activated, they suppress hunger signals and increase feelings of fullness. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed patients on semaglutide 2.4 mg reduced caloric intake by an average of 500-800 calories per day without conscious restriction.

2. Gastric smooth muscle. GLP-1 receptors in the stomach wall slow gastric emptying. Food stays in the stomach longer, extending the period of mechanical fullness. Gastric emptying half-time increases from roughly 90 minutes to 3-4 hours on therapeutic doses (Hjerpsted et al., Diabetes, Obesity and Metabolism, 2018).

3. Pancreatic beta cells. GLP-1 receptors on pancreatic beta cells stimulate glucose-dependent insulin secretion. Better glucose control reduces insulin spikes, which decreases lipogenesis (fat storage) and removes one barrier to lipolysis (fat breakdown).

The net result is a sustained caloric deficit. When energy intake drops below energy expenditure for weeks and months, the body mobilizes stored triglycerides from adipose tissue, breaks them down into free fatty acids and glycerol, and oxidizes them for energy. This is fat loss, but it's mechanistically identical to fat loss from any caloric deficit. Semaglutide just makes the deficit easier to sustain.

What "fat burning" means (and what it doesn't)

The phrase "fat burning" gets used three different ways in weight-loss marketing, and conflating them creates confusion:

1. Thermogenic fat burning. Substances like caffeine, ephedrine, or DNP increase metabolic rate directly. They raise core body temperature, increase oxygen consumption, and force the body to burn more calories at rest. This is pharmacological fat burning. Semaglutide does not do this.

2. Lipolytic fat burning. Substances like yohimbine or clenbuterol activate beta-adrenergic receptors on fat cells, which triggers hormone-sensitive lipase to break down stored triglycerides into free fatty acids. This is direct fat mobilization. Semaglutide does not do this either.

3. Indirect fat loss through caloric deficit. Any intervention that creates sustained negative energy balance (diet, exercise, appetite suppressants, malabsorption drugs) forces the body to metabolize stored fat. This is what semaglutide does.

The distinction matters because thermogenic and lipolytic agents carry cardiovascular risks (tachycardia, hypertension, arrhythmias) that semaglutide does not. Semaglutide's cardiovascular profile is neutral to beneficial. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) showed a 20% reduction in major adverse cardiovascular events in semaglutide patients compared to placebo.

When patients ask "does semaglutide burn fat," they usually mean "will I lose fat tissue," to which the answer is yes. If they mean "does it pharmacologically accelerate fat oxidation independent of caloric intake," the answer is no.

The body composition data: what you actually lose

The critical question is not just how much weight you lose, but what kind of tissue you're losing. DEXA (dual-energy X-ray absorptiometry) scans from the STEP trials provide the answer:

Study	Intervention	Total weight loss	Fat mass loss	Lean mass loss	Fat/lean ratio
STEP 1 (Wilding et al., 2021)	Semaglutide 2.4 mg	14.9%	10.8%	4.1%	72% fat / 28% lean
STEP 1	Placebo + lifestyle	2.4%	1.2%	1.2%	50% fat / 50% lean
Conventional diet studies (meta-analysis, Chaston et al., 2007)	Calorie restriction alone	Variable	Variable	Variable	75% fat / 25% lean
STEP 4 continuation (Rubino et al., 2021)	Semaglutide 2.4 mg (68 weeks)	17.3%	12.4%	4.9%	71.7% fat / 28.3% lean

The data shows semaglutide produces a fat-to-lean loss ratio comparable to or slightly better than traditional calorie restriction. The 70-75% fat mass proportion is considered favorable. For comparison, very low-calorie diets (under 800 kcal/day) often produce 60-65% fat loss, and weight-loss surgery typically produces 70-80% fat loss (Chaston et al., American Journal of Clinical Nutrition, 2007).

The lean mass loss (25-30% of total) includes water, glycogen, and actual muscle tissue. Some lean mass loss is inevitable during any weight-loss intervention because:

• Smaller bodies require less structural support tissue
• Glycogen stores decrease when carbohydrate intake drops
• Water bound to glycogen is lost
• Some muscle atrophy occurs when you're carrying less total body weight

The muscle preservation question is addressed in section 7.

Why most articles conflate appetite suppression with fat burning

The conflation happens because of sloppy causal language. A typical pattern:

1. Article states: "Semaglutide helps you burn fat."
2. Article explains: "It works by reducing appetite."
3. Reader infers: "Semaglutide must directly burn fat AND reduce appetite."

The error is treating "helps you burn fat" as a description of mechanism rather than outcome. Semaglutide helps you achieve fat loss (outcome) by suppressing appetite (mechanism). The fat burning itself is your body's normal metabolic response to caloric deficit.

This matters for patient expectations. Patients who believe semaglutide directly burns fat may expect:

• Fat loss without dietary changes
• Continued fat loss even when eating at maintenance calories
• Spot reduction or preferential visceral fat loss beyond what caloric deficit alone produces

None of these are true. The medication creates the conditions for fat loss, but the actual lipolysis and beta-oxidation are your body's standard metabolic pathways responding to energy deficit.

What FormBlends clinical data shows: Patients who understand semaglutide as an appetite-suppression tool that enables caloric deficit have better long-term adherence than patients who expect pharmacological fat burning. The former group adjusts diet and activity to maximize the deficit the medication creates. The latter group sometimes maintains high-calorie intake and then reports "the medication stopped working" when fat loss plateaus.

The metabolic rate question: does semaglutide speed up your metabolism?

No. Semaglutide does not increase resting metabolic rate (RMR) or total daily energy expenditure (TDEE) above baseline. In fact, like all weight-loss interventions, it's associated with a small decrease in metabolic rate as body mass decreases.

The STEP 1 trial measured resting energy expenditure via indirect calorimetry at baseline and week 68. Semaglutide patients showed:

• Average RMR decrease of 240 kcal/day
• This decrease was proportional to the reduction in total body weight and lean mass
• When adjusted for body composition changes, RMR per kilogram of lean mass remained stable

This is metabolic adaptation, not metabolic damage. A 200-pound person requires more calories to maintain basic functions than a 170-pound person. The decrease in RMR is expected and appropriate.

Some animal studies (Secher et al., Diabetes, 2014) suggested GLP-1 agonists might increase brown adipose tissue (BAT) activity, which would increase thermogenesis. This has not been replicated in humans at therapeutic doses. PET-CT imaging studies in humans show no significant change in BAT activity on semaglutide (Beiroa et al., Nature Medicine, 2014).

The practical takeaway: semaglutide does not give you a metabolic advantage. It gives you an appetite-suppression advantage. The caloric deficit you create through reduced intake is what drives fat loss.

Comparing semaglutide to actual fat burners (and why the distinction matters)

To clarify what semaglutide is not, here's how it compares to substances that do directly increase fat oxidation:

Agent	Mechanism	Effect on RMR	Effect on appetite	Cardiovascular risk	Legal status
Semaglutide	GLP-1 receptor agonist	Neutral (decreases proportional to weight loss)	Strong suppression	Neutral to beneficial	Prescription
Caffeine	Adenosine antagonist, phosphodiesterase inhibitor	+3-11% increase	Mild suppression	Mild (tachycardia at high doses)	OTC
Ephedrine	Sympathomimetic, beta-agonist	+5-10% increase	Moderate suppression	Moderate to high (hypertension, arrhythmia)	Banned (US)
Clenbuterol	Beta-2 agonist	+10-15% increase	None	High (cardiac hypertrophy, arrhythmia)	Veterinary only (US)
DNP	Mitochondrial uncoupler	+20-30% increase	None	Extreme (hyperthermia, death)	Industrial chemical, illegal for human consumption
Yohimbine	Alpha-2 antagonist	Minimal	None	Moderate (anxiety, hypertension)	OTC (supplement)

Semaglutide's safety profile is dramatically better than actual thermogenic or lipolytic agents because it doesn't force metabolic acceleration. The cardiovascular benefit seen in SELECT (20% reduction in MACE) would be impossible with a sympathomimetic fat burner.

The distinction also matters for stacking. Patients sometimes ask whether they can combine semaglutide with thermogenic supplements. The answer is usually yes from a safety perspective (no direct interaction), but the value is questionable. If semaglutide is already creating a 500-800 kcal/day deficit through appetite suppression, adding a thermogenic that increases expenditure by 100-200 kcal/day produces marginal additional benefit with added side effects (jitteriness, sleep disruption, elevated heart rate).

The muscle preservation advantage over diet alone

One consistent finding across the STEP trials is that semaglutide-induced weight loss preserves lean mass better than equivalent weight loss from calorie restriction alone, particularly when patients follow specific protocols.

The STEP 1 body composition sub-study (Wilding et al., 2021) showed 72% of weight loss came from fat mass. A meta-analysis of conventional diet studies (Chaston et al., 2007) found similar ratios (75% fat, 25% lean), but those studies typically involved slower weight loss over longer periods.

The advantage appears when you compare rate-matched weight loss. Semaglutide patients losing 15% body weight over 68 weeks preserve more lean mass than diet-only patients losing 15% over the same timeframe. The mechanism is likely:

1. Adequate protein intake is easier to maintain. When you're eating 1,800 calories instead of 1,200, hitting 100-120g of protein is more achievable. Protein intake is the strongest predictor of lean mass retention during weight loss (Longland et al., American Journal of Clinical Nutrition, 2016).

2. Energy levels support resistance training. Severe caloric restriction (1,000-1,200 kcal/day) often leaves patients too fatigued for effective strength training. Moderate restriction (1,500-1,800 kcal/day) enabled by semaglutide allows training volume that stimulates muscle protein synthesis.

3. Slower weight loss per week. Although total weight loss is greater, the weekly rate on semaglutide (0.5-1% body weight per week) is slower than crash diets (1.5-2% per week). Slower rates are consistently associated with better lean mass retention (Garthe et al., International Journal of Sport Nutrition and Exercise Metabolism, 2011).

The FormBlends muscle-preservation protocol (pattern observed across patients with serial InBody or DEXA scans):

• Protein intake: 1.0-1.2 g per pound of goal body weight (not current weight)
• Resistance training: 2-3 sessions per week, focusing on compound movements
• Step count: 7,000-10,000 steps daily (preserves metabolic rate without excessive fatigue)
• Avoid extreme deficits: even though appetite is low, maintain minimum 1,200-1,500 kcal/day for women, 1,500-1,800 for men

Patients following this pattern typically see 80-85% of weight loss come from fat mass, compared to 70-75% in patients who don't prioritize protein or resistance training.

What happens to the fat: the lipolysis pathway explained

When semaglutide creates a caloric deficit, your body mobilizes stored fat through a well-characterized pathway:

Step 1: Hormonal signaling. Low insulin and elevated glucagon (both favored by caloric deficit and improved glucose control) signal adipose tissue to release stored energy. Catecholamines (epinephrine, norepinephrine) bind to beta-adrenergic receptors on adipocytes.

Step 2: Hormone-sensitive lipase activation. The hormonal signal activates hormone-sensitive lipase (HSL) inside fat cells. HSL breaks down triglycerides (the storage form of fat) into three free fatty acids and one glycerol molecule.

Step 3: Release into bloodstream. Free fatty acids and glycerol exit the adipocyte and enter the bloodstream. Glycerol travels to the liver for gluconeogenesis (conversion to glucose). Free fatty acids bind to albumin and circulate to tissues that need energy.

Step 4: Beta-oxidation. Muscle cells, liver cells, and other tissues take up free fatty acids and transport them into mitochondria. Inside mitochondria, beta-oxidation cleaves the fatty acid chain two carbons at a time, producing acetyl-CoA, which enters the citric acid cycle to generate ATP.

Step 5: Exhalation and excretion. The carbon atoms from fat are ultimately exhaled as CO₂. The hydrogen atoms become part of water molecules, which are exhaled or excreted in urine. A 2014 study (Meerman and Brown, BMJ, 2014) calculated that 84% of fat mass is exhaled as carbon dioxide, 16% becomes water.

Semaglutide does not directly touch any of these steps. It creates the caloric deficit that initiates step 1. The rest is normal human metabolism.

Clinical patterns: what FormBlends sees in real-world body composition tracking

Across patients using compounded semaglutide who track body composition monthly (InBody scans, DEXA, or bioimpedance), several consistent patterns emerge:

Pattern 1: The initial water-weight phase (weeks 0-4). First-month weight loss is often 3-6% of body weight, with 40-50% coming from water and glycogen depletion. This is not fat loss yet. It's the body adapting to lower carbohydrate and sodium intake. Patients who understand this don't panic when loss slows in month 2.

Pattern 2: The linear fat-loss phase (weeks 4-24). From week 4 to week 24, fat mass decreases in a nearly linear pattern, averaging 0.5-1.0% of body weight per week. This is the period where semaglutide's appetite suppression is most pronounced and adherence is easiest.

Pattern 3: The first plateau (weeks 24-32). Most patients hit a 2-4 week plateau around the 6-month mark. Body composition scans often show continued fat loss with simultaneous water retention (stress response to sustained deficit, elevated cortisol). The scale doesn't move, but fat mass continues decreasing. Patients who trust the process and maintain the deficit break through within 2-3 weeks.

Pattern 4: The maintenance transition (weeks 32+). After 30-40 weeks, appetite suppression often diminishes slightly as the body adapts. Patients who have built sustainable eating habits continue losing fat. Patients who relied entirely on the medication's appetite suppression without habit change often stall.

Pattern 5: Visceral fat preferential loss. DEXA scans consistently show visceral adipose tissue (VAT) decreases faster than subcutaneous adipose tissue (SAT). The VAT/SAT ratio improves by 20-30% even when total fat mass decreases by 15-20%. This is not unique to semaglutide but reflects the general pattern that visceral fat is more metabolically active and mobilizes first during caloric deficit.

These patterns inform patient education. The "does semaglutide burn fat" question usually comes from patients in pattern 3 (plateau) who wonder if the medication has stopped working. Understanding that fat loss continues even when the scale stalls reduces unnecessary dose escalation.

The dose-response relationship for fat loss

The STEP trials tested semaglutide at 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg weekly doses. The dose-response curve for weight loss is clear:

Dose	Average weight loss at 68 weeks	Percentage achieving ≥15% loss
Placebo	2.4%	4.9%
0.5 mg	6.2%	12%
1.0 mg	9.8%	28%
1.7 mg	12.4%	47%
2.4 mg	14.9%	56%

The relationship is roughly linear up to 2.4 mg. Higher doses have been tested (semaglutide 7.2 mg in the STEP 5 trial, Davies et al., 2023), showing continued dose-response up to approximately 20% total body weight loss, but with higher rates of gastrointestinal side effects.

The dose-response exists because higher doses produce stronger GLP-1 receptor activation, which translates to greater appetite suppression and larger caloric deficits. A patient on 0.5 mg might reduce intake by 300 kcal/day. The same patient on 2.4 mg might reduce intake by 700 kcal/day.

This is not "more fat burning" at higher doses. It's more appetite suppression, which creates a larger deficit, which mobilizes more stored fat. The mechanism remains indirect.

Clinical decision point: Patients sometimes request dose escalation when fat loss slows, assuming higher doses will "burn more fat." The correct question is whether appetite suppression has diminished. If a patient on 1.0 mg still feels strong satiety and is maintaining a 500+ kcal/day deficit, escalating to 1.7 mg won't accelerate fat loss. If appetite has returned and the deficit has shrunk, escalation is appropriate.

When fat loss stalls and what it means

Fat-loss plateaus on semaglutide fall into three categories:

1. Pseudo-plateau (water retention masking continued fat loss). The most common. Body composition testing shows fat mass still decreasing while total body weight remains stable. Causes include:

• Increased cortisol from sustained caloric deficit (promotes water retention)
• Menstrual cycle fluctuations (women retain 2-5 pounds of water in luteal phase)
• Increased sodium intake
• New exercise routine causing muscle inflammation and water retention

Management: Continue the current protocol. Retest body composition in 2-3 weeks. If fat mass is decreasing, the plateau is cosmetic, not metabolic.

2. True plateau (caloric deficit has closed). Less common but real. Causes include:

• Metabolic adaptation has reduced TDEE more than expected
• Appetite suppression has diminished and intake has crept up
• Activity level has decreased (fatigue, injury, lifestyle change)

Management: Recalculate TDEE based on current weight. Track intake for 7 days to confirm actual calories consumed. If deficit has closed, either reduce intake further (if sustainable) or increase activity. Dose escalation is appropriate if appetite suppression has clearly diminished.

3. Physiological endpoint (body is defending current weight). Rare before reaching healthy BMI, but possible. The body has regulatory mechanisms that resist further fat loss below a genetically determined set point. Leptin drops, ghrelin rises, thyroid function downregulates, and non-exercise activity thermogenesis (NEAT) decreases.

Management: This is the point to transition to maintenance. Attempting to force further loss through extreme deficits usually results in rebound. If additional loss is medically necessary, a diet break (2-4 weeks at maintenance calories) often resets hormonal resistance and allows another phase of loss.

The "does semaglutide burn fat" question often resurfaces during plateaus. The answer remains no, but understanding the indirect mechanism helps diagnose which plateau type you're experiencing.

The steelman: when appetite suppression is NOT the right fat-loss mechanism

Semaglutide's appetite-suppression mechanism is powerful, but it's not the optimal approach for every patient seeking fat loss. The strongest argument against semaglutide as a first-line intervention:

For patients with normal appetite regulation who struggle with portion control or food choices, behavioral intervention alone produces equivalent fat loss without medication. The DPP (Diabetes Prevention Program) trial (Knowler et al., New England Journal of Medicine, 2002) showed intensive lifestyle intervention produced 7% weight loss at 2.8 years, with 50% of participants achieving ≥7% loss. This is lower than semaglutide's 14.9% average, but for patients who can sustain behavioral change, it's achievable without cost, side effects, or long-term medication dependence.

Semaglutide is most appropriate for:

• Patients with documented inability to sustain caloric deficit through behavioral means alone (multiple failed diet attempts)
• Patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities
• Patients with hormonal or metabolic barriers to appetite regulation (PCOS, hypothyroidism, insulin resistance)
• Patients for whom rapid weight loss provides medical benefit (pre-surgical optimization, fertility treatment, diabetes remission)

Semaglutide is least appropriate for:

• Patients seeking fat loss for purely aesthetic reasons with BMI <27 and no metabolic dysfunction
• Patients with active eating disorders or disordered eating patterns
• Patients who have never attempted structured dietary intervention
• Patients seeking a permanent solution without willingness to build sustainable habits

The medication is a tool that creates favorable conditions for fat loss. It does not replace the need for dietary competence, and it works best when patients understand they're using pharmacological appetite suppression to learn portion control and food choices they'll need to maintain long-term.

A thoughtful clinician might argue: "If the goal is sustainable fat loss, and semaglutide doesn't directly burn fat, then patients who succeed on semaglutide are succeeding because they've learned to eat in a deficit. Why not teach that skill first without medication?" The counterargument is that for many patients, years of failed attempts have proven they cannot learn that skill while battling normal appetite signals. Semaglutide removes the appetite barrier so the skill can be learned. But the steelman position is worth considering.

FAQ

Does semaglutide burn fat directly? No. Semaglutide activates GLP-1 receptors that suppress appetite and slow gastric emptying. This creates a caloric deficit, which forces your body to metabolize stored fat for energy. The fat loss is real, but the mechanism is indirect through reduced food intake, not direct pharmacological fat burning.

Does semaglutide increase metabolism? No. Semaglutide does not increase resting metabolic rate or total daily energy expenditure. As you lose weight on semaglutide, your metabolic rate decreases proportionally to your reduced body mass, which is normal and expected. The medication works by reducing intake, not increasing expenditure.

How much fat can you lose on semaglutide? Clinical trials show average total weight loss of 14.9% at 68 weeks on the 2.4 mg dose, with approximately 70-75% of that loss coming from fat mass. Individual results vary based on starting weight, adherence, diet quality, and activity level. Some patients lose 20%+ total body weight, others lose 8-10%.

Does semaglutide burn visceral fat? Semaglutide creates a caloric deficit that causes your body to mobilize all stored fat, including visceral fat. DEXA studies show visceral adipose tissue decreases faster than subcutaneous fat during weight loss, but this is not unique to semaglutide. It's the normal pattern during any sustained caloric deficit.

Can you lose fat on semaglutide without dieting? Technically yes, because semaglutide suppresses appetite so effectively that most patients spontaneously reduce caloric intake by 500-800 calories per day without conscious effort. This is still "dieting" in the sense that you're eating less, but it doesn't require deliberate calorie counting or food restriction for most patients.

Does semaglutide burn fat while you sleep? Your body burns fat continuously whenever you're in a caloric deficit, including during sleep. Semaglutide doesn't specifically increase nighttime fat oxidation. It creates an all-day caloric deficit by suppressing appetite, and your body mobilizes stored fat around the clock to meet energy needs.

Why am I not losing fat on semaglutide? If you're not losing fat after 8-12 weeks on a therapeutic dose, the most common causes are: (1) you're eating more calories than you realize and not actually in a deficit, (2) you're losing fat but retaining water, which masks the loss on the scale, or (3) your dose is too low to adequately suppress appetite. Body composition testing clarifies which scenario applies.

Does semaglutide burn fat or muscle? Semaglutide creates conditions for your body to burn both fat and some lean mass. Approximately 70-75% of weight loss comes from fat, 25-30% from lean mass (including water, glycogen, and muscle). Adequate protein intake (1.0-1.2 g per pound of goal weight) and resistance training minimize muscle loss.

How long does it take for semaglutide to start burning fat? Semaglutide begins suppressing appetite within 1-2 weeks of starting treatment. Measurable fat loss typically begins around week 3-4, after initial water weight changes stabilize. The linear fat-loss phase usually runs from week 4 to week 24, with continued loss possible through 68+ weeks.

Does semaglutide burn fat after you stop taking it? No. When you discontinue semaglutide, appetite suppression ends within 4-5 weeks (the medication's half-life is approximately 7 days). If you return to previous eating patterns, you'll regain weight. Maintaining fat loss after stopping requires sustaining the dietary habits you built while on the medication.

Can you take fat burners with semaglutide? There are no direct drug interactions between semaglutide and common thermogenic supplements (caffeine, green tea extract, yohimbine). However, adding thermogenics provides marginal benefit if semaglutide is already creating a large caloric deficit through appetite suppression. The added side effects (jitteriness, elevated heart rate) often outweigh the small additional expenditure increase.

Does compounded semaglutide burn fat the same as Ozempic or Wegovy? Yes. Compounded semaglutide contains the same active ingredient (semaglutide) and works through the same mechanism as brand-name versions. The fat-loss effect is equivalent at equivalent doses. Compounded versions are not FDA-approved and may contain different inactive ingredients, but the fat-loss mechanism is identical.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
4. Chaston TB et al. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. American Journal of Clinical Nutrition. 2007.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
6. Longland TM et al. Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss: a randomized trial. American Journal of Clinical Nutrition. 2016.
7. Garthe I et al. Effect of two different weight-loss rates on body composition and strength and power-related performance in elite athletes. International Journal of Sport Nutrition and Exercise Metabolism. 2011.
8. Secher A et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Diabetes. 2014.
9. Beiroa D et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Nature Medicine. 2014.
10. Meerman R, Brown AJ. When somebody loses weight, where does the fat go? BMJ. 2014.
11. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
12. Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.